StreetInsider.com News Articles

Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Fri, 17 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260717/26784698.html

Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Fri, 17 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260717/26784698.html

Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Fri, 17 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260717/26784698.html

Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Fri, 17 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260717/26784698.html

Immuneering Corporation Announces Grants of Inducement Awards

Fri, 17 Jul 2026 16:05:00 -0400

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the “Start Date”). In connection with the commencement of Mr. Gengos’s employment, on July 16, 2026, Mr. Gengos was granted an option to purchase 650,000 shares of the Company’s Class A common stock (“Common Stock”) with a per share exercise price of $4.78, the closing trading price

Immuneering Corporation Announces Grants of Inducement Awards

Fri, 17 Jul 2026 16:05:00 -0400

Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Thu, 16 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260716/26779778.html

Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Thu, 16 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260716/26779778.html

Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Thu, 16 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260716/26779778.html

Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Thu, 16 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260716/26779778.html

Immuneering Corporation (IMRX) 7500 contracts of August 75 calls as share price up 6.2%

Wed, 08 Jul 2026 14:34:33 -0400

Immuneering Corporation (NASDAQ: IMRX) 30-day option implied volatility is at 83; compared to its 52-week range of 46 to 203 with a focus on 7500 contracts of August 75 calls as share price up 6.2%.

Cantor Fitzgerald Starts Immuneering Corporation (IMRX) at Overweight

Wed, 08 Jul 2026 06:06:32 -0400

Cantor Fitzgerald analyst Li Watsek initiates coverage on Immuneering Corporation (NASDAQ: IMRX) with a Overweight rating.

The analyst comments "Immuneering (IMRX) is a late-stage oncology company advancing a new class of cancer therapies - deep cyclic inhibitors (DCIs) - designed to deliver deeper and more durable pathway suppression than conventional inhibitors. Its lead asset, atebimetinib, a DCI MEK inhibitor, is being evaluated in a Ph3 trial for first-line metastatic pancreatic cancer (1L mPDAC), one of oncology's highest-unmet-need indications. We believe the market materially underestimates both the probability of Ph3 success and the commercial opportunity of atebi. For long-term investors, or those

Cantor Fitzgerald Starts Immuneering Corporation (IMRX) at Overweight

Wed, 08 Jul 2026 06:06:32 -0400

Cantor Fitzgerald analyst Li Watsek initiates coverage on Immuneering Corporation (NASDAQ: IMRX) with a Overweight rating.

Kalaris Therapeutics names Laurie Keating to its board